1-Ethyl-3-methyl-5H-imidazo[1,5-a]quinoxalin-4-one | 134485-90-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 1-Ethyl-3-methyl-5H-imidazo[1,5-a]quinoxalin-4-one
• CAS: 134485-90-8
• 化学式: C₁₃H₁₃N₃O
• 分子量: 227.266
• InChiKey: PBRFQQAUEOPPGQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  46.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-Ethyl-3-methyl-5H-imidazo[1,5-a]quinoxalin-4-one 在 N,N-二乙基苯胺 、 三氯氧磷 作用下， 反应 5.0h， 以81%的产率得到4-chloro-1-ethyl-3-methylimidazo<1,5-a>quinoxaline
  参考文献：
  名称：

  Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogs

  摘要：

  A series of novel imidazoquinoxalinones and their aza analogues were prepared by the cyclization of o-amino(H-1-imidazol-1-yl)aryls and heteroaryls with carbonyldiimidazole. The compounds were screened for inhibition of Type I and Type IV phosphodiesterases (PDE's) and evaluated for their vasorelaxant and positive inotropic activities in vitro. In general, compounds having potent PDE inhibitory activity also possessed good inotropic and vasodilator activity, although linear correlations between these activities could not be established.

  DOI：

  10.1021/jm00113a002
• 作为产物：
  描述：

  1-氟-2-硝基苯 在 palladium on activated charcoal 氢气 、 potassium carbonate 作用下， 以 乙醇 、 乙腈 为溶剂， 25.0 ℃ 、344.73 kPa 条件下， 反应 27.5h， 生成 1-Ethyl-3-methyl-5H-imidazo[1,5-a]quinoxalin-4-one
  参考文献：
  名称：

  Novel compounds possessing potent cAMP and cGMP phosphodiesterase inhibitory activity. Synthesis and cardiovascular effects of a series of imidazo[1,2-a]quinoxalinones and imidazo[1,5-a]quinoxalinones and their aza analogs

  摘要：

  A series of novel imidazoquinoxalinones and their aza analogues were prepared by the cyclization of o-amino(H-1-imidazol-1-yl)aryls and heteroaryls with carbonyldiimidazole. The compounds were screened for inhibition of Type I and Type IV phosphodiesterases (PDE's) and evaluated for their vasorelaxant and positive inotropic activities in vitro. In general, compounds having potent PDE inhibitory activity also possessed good inotropic and vasodilator activity, although linear correlations between these activities could not be established.

  DOI：

  10.1021/jm00113a002

文献信息

• BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA
  申请人：Combrink Keith D.

  公开号：US20120046285A1

  公开（公告）日：2012-02-23

  The invention provides compositions and methods for treating and/or preventing ocular disorders associated with increased intraocular pressure. In particular, the compounds are bradykinin agonists.

  这项发明提供了用于治疗和/或预防与眼内压增高相关的眼部疾病的组合物和方法。具体来说，这些化合物是激肽酶激动剂。
• Methods, compositions, and kits for the treatment of ophthalmic disorders
  申请人：CombinatoRx, Inc.

  公开号：EP2218442A1

  公开（公告）日：2010-08-18

  The invention features methods, compositions and kits comprising a corticosteroid and a non-steroidal immunophilin-dependent immunosuppressant for treating an ophthalmic disorder in a patient, wherein at least one of said corticosteroid and said non-steroidal immunophilin-dependent immunosuppressant is present at a low concentration, in particular wherein said corticosteroid is prednisolone acetate and said non-steroidal immunophilin-dependent immunosuppressant is cyclosporine A.

  本发明的特征是包含皮质类固醇和非类固醇免疫嗜血素依赖性免疫抑制剂的方法、组合物和试剂盒，用于治疗患者的眼科疾病、其中，所述皮质类固醇和所述非类固醇免疫嗜血素依赖性免疫抑制剂中至少有一种以低浓度存在，特别是所述皮质类固醇为醋酸泼尼松龙，所述非类固醇免疫嗜血素依赖性免疫抑制剂为环孢素 A。
• 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one cGMP-PDE inhibitors for the treatment of erectile dysfunction
  申请人：——

  公开号：US20010044441A1

  公开（公告）日：2001-11-22

  6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one compounds which are selective inhibitors of cGMP PDE are useful in the treatment of erectile dysfunction (impotence) in male animals, including man.

  6-terocyclyl吡唑[3,4-d]嘧啶-4-酮化合物是cGMP PDE的选择性抑制剂，可用于治疗雄性动物（包括人类）的勃起功能障碍（阳痿）。
• Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
  申请人：——

  公开号：US20020004498A1

  公开（公告）日：2002-01-10

  A method is provided for treating erectile dysfunction in a mammalian male individual. The method involves the transmucosal administration of a phosphodiesterase inhibitor or a pharmaceutically acceptable salt, ester, amide or derivative thereof, within the context of an effective dosing regimen. Preferred modes of administration include transbuccal, sublingual and transrectal routes. Pharmaceutical formulations and kits are provided as well.

  提供了一种治疗哺乳动物男性个体勃起功能障碍的方法。该方法包括在有效给药方案的范围内，经粘膜给药磷酸二酯酶抑制剂或其药学上可接受的盐、酯、酰胺或衍生物。首选的给药方式包括经口腔、舌下和经直肠途径。此外，还提供药物制剂和试剂盒。
• Co-administration of a prostaglandin and an androgenic agent in the treatment of female sexual dysfunction
  申请人：——

  公开号：US20010051656A1

  公开（公告）日：2001-12-13

  Methods and formulations for treating female sexual dysfunction are provided. A pharmaceutical composition formulated so as to contain a selected vasoactive agent is administered to the vagina, vulvar area or urethra of the individual undergoing treatment. Suitable vasoactive agents are vasodilators, including naturally occurring prostaglandins, synthetic prostaglandin derivatives, endothelial-derived relaxation factors, vasoactive intestinal polypeptide agonists smooth muscle relaxants leukotriene inhibitors, and other. The formulations are also useful for preventing the occurrence of yeast infections, improving vaginal muscle tone and tissue health, enhancing vaginal lubrication, and minimizing excess collagen deposition. A clitoral drug delivery device is also provided.

  本文提供了治疗女性性功能障碍的方法和制剂。在接受治疗者的阴道、外阴部或尿道中注入一种药物组合物，使其含有一种选定的血管活性剂。合适的血管活性剂是血管扩张剂，包括天然前列腺素、合成前列腺素衍生物、内皮衍生松弛因子、血管活性肠道多肽激动剂平滑肌松弛剂白三烯抑制剂等。这些制剂还可用于预防酵母菌感染的发生，改善阴道肌肉张力和组织健康，增强阴道润滑度，并最大限度地减少胶原蛋白的过度沉积。此外，还提供了一种阴蒂给药装置。